THE BEST SIDE OF TRASTUZUMAB PACKAGE INSERT

Among the most below-investigated “driving forces” involved in trastuzumab resistance is PTEN. Nagata et al. (2004) reported which the loss of PTEN was noticed in 36% of HER2-beneficial Most important breast tumor specimens from sufferers with stage IV ailment. Additionally, Additionally they confirmed that individuals with PTEN-deficient tumor